Bifogade filer
Prostatype Genomics Annual Report 2024 ENG
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Prostatype Genomics AB today publishes the Annual Report for the financial year of 2024. The translated Annual Report is attached as a PDF and is available on the company's webpage: www.prostatypegenomics.com
Please note that the English version is a translation of the Swedish original.
For more information, please contact:
Fredrik Rickman, CEO Prostatype Genomics AB
Telephone: +46 (0) 73 049 77 01
e-mail: fredrik.rickman@prostatypegenomics.com
About Prostatype Genomics AB
Prostatype® is a genomic test that is available to patients and treating urologists as a complementary decision basis for the question of treatment or no-treatment of prostate cancer. The test was developed by a leading research group at Karolinska Institute and is provided by Prostatype Genomics AB.
Certified Adviser
Carnegie Investment Bank AB (publ)
Telephone: +46 (0)73 856 42 65
E-mail: certifiedadviser@carnegie.se